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Abstract
The World Health Organisation (WHO) classification categorises musculoskeletal soft tissue tumours (STT) based 
on their similarity to normal adult tissue. The most recent WHO classification provides an updated scheme that in­
tegrates biological behaviour as a distinguishing feature in each subcategory; STTs are further subdivided as benign, 
intermediate (locally aggressive or rarely metastasising), and malignant. Although malignant STTs are infrequent in 
routine orthopaedic radiology practice, musculoskeletal radiologists must be familiar with the imaging appearance 
of malignant STTs and distinguish them from their benign counterparts for appropriate management. Magnetic res­
onance imaging (MRI) is the ideal modality for the detection, characterisation, and local staging of STT. This review 
will discuss the most recent updates to the WHO classification of STT that are relevant to radiologists in a routine 
clinical practice with MRI correlation. The utility of advanced MRI sequences such as diffusion weighted imaging, 
dynamic contrast enhanced sequences, and magnetic resonance spectroscopy to provide insight into the biological 
behaviour of various STTs is highlighted. 
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Introduction
The World Health Organisation (WHO) classification cate­
gorises soft tissue tumours (STT) based on their similarity 
to normal adult tissue. Namely, each STT is categorised as 
adipocytic, fibroblastic/myofibroblastic (F/M), so­called 
fibrohistiocytic, smooth­muscle, pericytic, vascular, skele­
tal­muscle, nerve sheath, gastrointestinal stromal tumours, 
and tumours of uncertain differentiation [1]. The most re­
cent WHO classification, edited in 2013, integrates novel 
genetic data and provides an updated classification scheme 
that integrates biological behaviour as a distinguishing fea­
ture in each subcategory; STTs are further sub­grouped as 
benign, intermediate (locally aggressive or rarely metasta­
sizing), and malignant [2]. 
The vast majority of clinically encountered STTs are 
benign with an excellent prognosis after curative surgi­
cal excision. Only a small proportion of STTs are malig­
nant, although they require a multidisciplinary approach 
preferably at a sarcoma centre for optimal outcome. 
Although malignant STT or soft tissue sarcomas (STS) are 
infrequent in routine radiology practice, musculoskeletal 
radiologists must be familiar with their imaging appear­
ance to initiate the referral to an orthopaedic oncologist 
or tertiary referral centre. Radiologists play an important 
role in the initial characterisation of STTs, with careful 
analysis of their size, location, tissue layer (relationship 
or depth relative to the fascia), and overall anatomic ex­
tent including extra­compartmental extension and neu­
rovascular invasion. Magnetic resonance imaging (MRI) 
is the ideal modality for the detection, characterisation, 
and local staging of STT. This review will discuss the most 
recent updates to the WHO classification of STT that are 
relevant to radiologists in a clinical practice with MRI 
correlation. The role of advanced MRI sequences such 
as diffusion­weighted imaging (DWI), dynamic contrast 
enhanced sequences (DCE), and MR spectroscopy (MRS) 
are highlighted.
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Adipocytic tumours
Of all the STT, adipocytic tumours are the most common 
mesenchymal tumours [3]. The most recent edition of the 
WHO Classification of tumours of soft tissues has provided 
several updates to the adipocytic tumour category. In the 
benign adipocytic tumour sub­group, the updates include 
removal of myxolipoma as a diagnosis because these are 
now considered spindle cell variants. In addition, diffuse 
lipoblastoma is now the preferred term for lipoblastoma­
tosis. Of the benign adipocytic STT, spindle cell/pleomor­
phic lipoma can be challenging to accurately diagnose 
on imaging due to variable imaging appearances, lack of 
macroscopic fat on MRI or computed tomography (CT), 
and an overlapping imaging appearance with STS [4]. 
As such, although a simple lipoma can be diagnosed de­
finitively on MRI, spindle cell lipoma can be a diagnostic 
dilemma and requires a biopsy for definitive diagnosis. As 
of now, there are no advanced MRI sequences addressing 
this challenge.
For the intermediate (locally aggressive) category of adi­
pocytic tumours, atypical lipomatous tumour (ALT) is now 
divided into three main subgroups (adipocytic [lipoma­ 
like], sclerosing, and inflammatory types) rather than four, 
as in the past. Although the term spindle cell liposarcoma 
still exists in the text, the absence of MDM2 immunoposi­
tivity or 12q15 amplification in this tumour type suggests 
spindle cell liposarcoma and represents a separate group 
of STS. MDM2 and CDK4 immunohistochemistry and/or 
fluorescence in situ hybridisation for MDM2 gene ampli­
fication have come into widespread use for the diagnosis 
of ALT/well­differentiated liposarcoma (WDLPS) and de­
differentiated liposarcoma (DDLPS) [5]. Although ALT is 
the preferred term, the term WDLPS is used for a histo­
logically identical adipocytic tumour situated in anatomic 
locations where complete resection is not feasible, such as 
the mediastinum and retroperitoneum. A complete resec­
tion of a mediastinal or retroperitoneal WDLPS can be 
associated with significant morbidity by locally aggressive 
growth, recurrence, and extensive surgical resections that 
may require removal of multiple organs, while resection of 
a histologically identical tumour in the extremities (ALT) 
is less morbid. Using routine non­contrast and contrast­
enhanced routine MRI sequences (Figure 1), lesion size, lo­
cation (deep to the superficial fascia), proximal lower limb 
lesions, incomplete fat suppression, or increased architec­
tural complexity (thick septations > 2 mm and nodularity 
> 1 cm) have been shown to be independently predictive 
of ALT rather than benign lipoma [6]. There is no utility of 
advanced MRI sequences such as DWI for the distinction 
of benign, intermediate, and malignant adipocytic STT, 
and limited added value of DCE distinguish DDLPS from 
Figure 1. 86-year-old man with atypical lipomatous tumour. There is a 13.2 × 12.9 × 31.7 cm recurrent macroscopic fat-containing mass occupying 
the medial and posterior compartments of the right thigh visible on coronal (A) and axial (B) T1-weighted and fat-suppressed T2-weighted (C) magnetic 
resonance (MR) images. Although there is suppression of macroscopic fat on axial T2-weighted fat-suppressed MR image through the right thigh (C), 
MRI features concerning for atypical lipomatous tumour (ALT) including multiple thick septations, deep location, and large size are noted. Proximally and 
distally, the mass surrounds the sciatic nerve (dotted arrows on images A and B). There is a small defect in the right vastus lateralis muscle with interven-
ing fat and superficial fascia with extra-compartmental extension into the subcutaneous tissues (denoted by an * on images B and C and anterior thigh 
compartment (long arrows on images B and C. On routine non-contrast and contrast-enhanced routine MRI sequences, lesion size, tissue layer (deep to 
the superficial fascia), location (proximal lower limb), incomplete fat suppression, or increased architectural complexity (thick septations > 2 mm and 
nodularity > 1 cm) have been shown to be independently predictive of ALT rather than benign lipoma
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ALT [7], potentially providing a means of triaging patients 
toward follow­up rather than biopsy in lesions with high­
grade features.
Malignant adipocytic tumours (including DDLPS, 
myxoid liposarcoma, pleomorphic liposarcoma, and lipo­
sarcoma not otherwise specified) can be readily distin­
guished from both benign lipomas and ALTs due to the 
absence of significant intratumoural macroscopic fat. The 
term DDLPS is a new addition and refers to a tumour in 
which the high­grade or differentiated component of the 
tumour has adipocytic features similar to pleomorphic 
liposarcoma (referred to as homologous lipoblastic dif­
ferentiation or pleomorphic liposarcoma­like features).
Fibroblastic/myofibroblastic tumours
The 2013 WHO classification has made several changes in 
the fibroblastic/myofibroblastic (F/M) tumour category. 
Among the benign F/M tumours, nodular fasciitis, pre­
viously considered a reactive process, is now definitively 
established as a self­limiting neoplasm associated with 
rapid growth and ultimately spontaneous regression over 
the course of months based on MYH9­USP6 gene fu­
sion [8]. On histology, some cases may be worrisome for 
sarcoma, especially if biopsied during the active growth 
phase when abundant mitotic activity is present. On MRI, 
both proliferative myositis and nodular fasciitis appear as 
homogeneous masses with hypointensity or isointensity 
to skeletal muscle on anatomic images and as moderate 
or marked hyperintensity relative to skeletal muscle on 
T2­weighted images [9]. After administration of intra­
venous contrast (IV) material, nodular fasciitis tends to 
have homogeneous enhancement but can be variable [10]. 
Although the presence of a fascial tail [10] and close 
proximity to the superficial fascia are useful diagnostic 
clues, they are not determinate MRI features and histo­
logical confirmation is required [11]. Anatomic location 
is particularly useful in the definitive diagnosis of several 
benign F/M tumours including elastofibroma (Figure 2), 
fibromatosis colli, and fibroma of tendon sheath.
Of the benign STTs in this category, myositis ossifi­
cans (MO) remains a diagnostic dilemma because it is fre­
quently mistaken for a sarcoma and biopsied (Figure 3). 
Although MO is typically considered a non­neoplastic, 
post­traumatic entity, it is included as in the F/M tumour 
category based on the frequent presence of USP6 rear­
rangement, similar to nodular fasciitis [12]. On MRI, MO 
has a non­specific appearance in its early (< 4 weeks) and 
intermediate (4­8 weeks) imaging as a heterogeneous, 
intramuscular mass that is isointense or slightly hyper­
intense on T1­weighted imaging and hyperintense on 
T2­weighted imaging, with diffuse and avid enhance­
ment after the administration of IV contrast material, 
and extensive soft tissue oedema [13]. The presence of 
extensive perilesional muscle oedema as a useful imag­
ing feature for the distinction of early/intermediate stage 
MO from STS offers moderate sensitivity of 60­70% and 
excellent specificity of 97­99% [13]. Faint peripheral cal­
cification is visible in the early stage, which progresses to 
variable thickness calcification in the intermediate stage. 
The combination of typical MRI features in STT measur­
ing less than 5 cm, extensive perilesional oedema, history 
of trauma, and faint peripheral zonal calcification can be 
diagnostic of MO and followed closely on imaging [13].
In the intermediate (locally aggressive) sub­group, 
palmar/plantar fibromatosis can also be diagnosed de­
finitively based on its anatomic location. Palmar/plantar 
fibromatosis (Figure 4) demonstrates multiple nodular 
or band­like soft tissue masses arising from the proximal 
palmar or plantar aponeurosis extending along the subcu­
taneous tissues with variable T1 and T2 signal intensities 
with associated heterogeneous enhancement depending 
on the content of collagen and cellularity, similar to the 
other fibromatoses [14]. Plantar fibromatosis manifests as 
Figure 2. 67-year-old woman with elastofibroma dorsi. Axial T1-weighted magnetic resonance (MR) image through the left chest wall (A) shows an un-
encapsulated mass-like abnormality deep to the scapula (arrow) with corresponding indistinct elevated signal on ADC map (B), late arterial enhancement 
on coronal DCE MIP (C), and confluent enhancement on static T1-weighted fat-suppressed post-contrast axial MR image (D). The mass was biopsied and 
confirmed to be elastofibroma
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a small cluster of multiple tumours along the deep plan­
tar aponeurosis, which typically blend with the adjacent 
plantar musculature. In the setting of a solitary tumour, 
the term plantar fibroma rather than fibromatosis may be 
used. Fascial tails along the aponeurosis are frequent.
Desmoids­type fibromatosis (Figure 5) also exhibits 
similar signal characteristics with fascial tails but occurs 
in the trunk. Desmoids often have band­like low signal in­
ternally, which can suggest the diagnosis, although this en­
tity can be diagnostically challenging and require a biopsy 
prior to definitive treatment [14]. Two new entities, giant 
cell fibroblastoma and dermatofibrosarcoma protuberans 
(DFSP), which were previously classified as skin tumour 
neoplasms, are new additions in the intermediate (rarely 
metastasising) sub­group. Giant cell fibroblastoma shows 
frequent local recurrence but has no metastatic potential. 
DFSP, on the other hand, shows not only locally aggressive 
behaviour but can also rarely transform into a fibrosarco­
ma and metastasise. DFSP tends to be subcutaneous in 
location with nonspecific T1 and T2 signal characteristics 
(Figure 6). Differential diagnosis of an aggressive subcuta­
neous STT includes DFSP, undifferentiated pleomorphic 
sarcoma (UPS)/fibrosarcoma, cutaneous/subcutaneous 
neoplasms (melanoma) and metastatic disease [14].
Lastly, myofibroma/myofibromatosis are now de­
scribed under the categories of pericytic tumours and sol­
itary fibrous tumour, haemangiopericytoma, lipomatous 
haemangiopericytoma, and giant cell angiofibroma and 
are all re­categorised as solitary fibrous tumours (SFT). 
On MRI, SFTs are nonspecific, well­defined, ovoid, and 
heterogeneously enhancing with regions of intra­lesional 
low signal intensity on fluid­sensitive sequences that cor­
respond to dense collagen and a vascular pedicle [15,16]. 
On DCE­MRI, the fibrous variety of SFTs tends to differ 
Figure 3. 20-year-old man with right paraspinal mass. Axial T1-weighted (A), T2-weighted (B), and T1-weighted post-contrast (C) magnetic resonance 
(MR) images through the thoracolumbar junction show a right paraspinal soft tissue mass (arrows) that was initially characterised as an indeterminate 
soft tissue mass suspicious for peripheral nerve sheath tumours (PNSTs) based on target sign visible on T2-weighted image (B) and paraspinal location. 
The patient underwent a biopsy, which was interpreted as a malignant PNST at an outside facility. The histological slides were re-interpreted as myositis 
ossificans (MO), cellular phase. Sequential axial computed tomography images through the lower thoracic spine at the time of initial presentation (D), in the 
intermediate stage (E), and late stage (F) reveal progressive zonal ossification peripherally compatible with MO (arrows). Although the presence of extensive 
perilesional muscle oedema is a useful imaging feature for the distinction of early/intermediate stage MO from sarcoma, it is not always visible, as in this case
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Figure 4. 32-year-old man with palmar fibromatosis. There is an unencapsulated, nodular soft tissue mass arising from the proximal palmar aponeurosis 
extending along the subcutaneous tissues (arrows) that is isointense to skeletal muscle on axial T1-weighted (A), hyperintense to skeletal muscle on axial 
T2-weighted fat-suppressed (B) with confluent internal enhancement on axial (C) and sagittal (D) T1-weighted fat-suppressed subtraction magnetic reso-
nance (MR) images through the hand. Fascial tails along the aponeurosis are visible (dotted arrow on image D). Coronal dynamic MR angiogram image (E) 
shows late arterial enhancement, a feature of benign disease
Figure 5. 40-year-old woman with desmoid type fibromatosis. Desmoids-type fibromatosis exhibits similar signal characteristics to palmar/plantar fibroma-
tosis with fascial tails but tends to occur in the trunk. Axial T1-weighted magnetic resonance image through the right anterior chest wall (A) shows an un-
encapsulated mass at the costochondral junction (arrow) with a corresponding indistinct low signal on T2-weighted image (B), and confluent enhancement 
on static T1-weighted fat-suppressed post-contrast axial image (C). Fascial tails (dotted arrows) along the chest wall are visible
Figure 6. 35-year-old male with dermatofibrosarcoma protuberans (DFSP). There is a 4.8 × 2.0 × 0.9 cm multilobulated T2 hyperintense (A), homoge-
neously enhancing dermal-based lesion (arrow) on axial T1-weighted post-contrast fat-suppressed image (B) through the pelvis located in the region of 
the left inguinal crease, with plaque-like thickening of the skin. DFSP, previously classified as a skin tumour, is a new addition in the intermediate (rarely 
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Figure 7. 66-year-old man with malignant fibroblastic/myofibroblastic tumour. Axial T2-weighted fat-suppressed magnetic resonance image through 
the right proximal thigh (A) shows an encapsulated 12 cm heterogeneous centrally higher signal intensity soft tissue mass located deep to the superficial 
fascia (arrow) with corresponding low-signal/restricted diffusion on ADC map (B), early arterial enhancement on coronal DCE MIP (C), and heterogeneous 
enhancement with intralesional necrosis on static coronal T1-weighted fat-suppressed post-contrast coronal image (D). The mass was biopsied and con-
firmed to be grade 2 myxofibrosarcoma
from its cellular counterparts, in that fibrous SFTs show 
progressive enhancement following contrast administra­
tion while cellular SFTs exhibit a rapid initial enhance­
ment pattern. On DWI, however, there is an overlap in the 
mean ADC values (× 10­3 mm2/s) of cellular and fibrous 
SFTs (1.4 ± 0.4 vs. 1.4 ± 0.5, respectively) [17]. There are 
no data regarding the utility of minimum ADC values in 
distinguishing these two kinds of SFT. There are no de­
terminate features of malignant F/M STT; however, the 
presence of restricted diffusion on DWI/ADC mapping 
and early arterial enhancement on DCE are indicators of 
malignancy (Figure 7).
So-called fibrohistiocytic tumours
Most commonly encountered so­called fibrohistiocytic 
tumours are benign and include tenosynovial giant cell 
tumour (TSGCT) (localised type, diffuse type, and malig­
nant) as well as deep benign fibrous histiocytoma. Fibroma 
of tendon sheath, a benign F/M tumour, can mimic a TS­
GCT. Both neoplasms can present clinically as indolent, 
slow­growing, painless masses located in close proximity 
to tendon sheaths, typically of the extremities. On MRI, 
both neoplasms tend to be low or variable signal intensity 
on non­contrast anatomic and fluid sensitive sequences, 
with little to no enhancement following contrast admin­
istration. Gradient echo (GRE) images can be useful to 
diagnose TSGCT based on the presence of susceptibility 
artifact (hemosiderin deposition). By other sequences, fi­
broma of tendon sheath appears as a nodular and mass­like 
lesion with a strip­like or irregular signal characteristics on 
fluid­sensitive sequence compared with the casting, mould 
morphology, and flaky/granular or separated pattern of 
TSGCT [18]. The latter distinguishing MRI features of­
fer high sensitivities (83­100%) and diagnostic accuracies 
(60­89%) but slightly lower specificities (29­79%) [18].
Intermediate (rarely metastasising) so­called fibro­
histiocytic tumours include plexiform fibrohistiocytic tu­
mour and giant cell tumour of soft tissue [1]. Malignant 
so­called fibrohistiocytic tumours, formerly known as ma­
lignant fibrous histiocytoma (MFH), and its subtypes have 
been renamed as undifferentiated sarcoma and are now 
classified under the undifferentiated/unclassified sarcomas 
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Smooth muscle tumours
The only change in this group has been the removal of 
angioleiomyoma, which is now included in the category 
of pericytic tumours [2]. 
Pericytic (perivascular) tumours
Pericytic (perivascular) tumours include glomus tumour 
and its variants as well as glomangiomatosis and, rarely, 
malignant glomus tumour. The 2013 WHO classification 
revised recommendations for the designation of glomus 
tumours as malignant and of uncertain malignant poten­
tial. The term malignant glomus tumours is used in the 
setting of marked nuclear atypia and any mitotic activity 
[2]. Tumour size greater than 2.0 cm and deep location are 
no longer criteria for malignancy, and tumours with these 
features but no nuclear atypia are now considered to be 
glomus tumours of uncertain malignant potential [2,19]. 
Glomus tumours can also be associated with Neurofibro­
matosis type 1 (NF1) and Horner syndrome. Although the 
majority of glomus tumours (65­75%) occur in the hand, 
with the most common location being the tip of the finger 
or toe, extra­digital glomus tumours also occur and present 
clinically as painful masses [19]. On MRI, the appearance 
of glomus tumours overlaps with other vascular neoplasms 
[20]. An additional major update in this category includes 
reclassification of myofibroma and myofibromatosis under 
myopericytoma rather than F/M tumours [2].
Skeletal muscle tumours
Although there have been modifications to the skeletal 
muscle tumour category based on advances in genetic mu­
tations associated different types of rhabdomyosarcoma, 
advanced MRI sequences have not provided similar insight 
into tumour category, and there are no diagnostic imaging 
features that enable diagnostic certainty without a biopsy.
Gastrointestinal stromal tumours 
Gastrointestinal stromal tumours (GISTs) were previously 
categorised under tumours of the digestive system but are 
now under the soft tissue tumour classification. GISTs can 
be benign, of uncertain malignant potential, and malig­
nant. The widely accepted National Comprehensive Can­
cer Network guidelines for risk stratification of GISTs are 
based on anatomic site, tumour size, and mitotic count, 
features determined to be highly predictive of malignant 
behaviour in several large retrospective studies [21,22]. 
Several qualitative and quantitative MRI and 18F­fluoro­
deoxyglucose positron emission tomography – computed 
tomography (18F­FDG PET/CT) features including ADC 
and maximum standard uptakes values (SUVmax) val­
ues can be useful in distinguishing non­GISTs, low­risk 
GISTs, and high­risk GISTs [23]. On multivariate analy­
sis, signal characteristics on T2­weighted imaging was the 
only independent variable for differentiating GISTs from 
non­GISTs (such as leiomyoma, schwannoma, and glo­
mus tumour) [23]. Enhancement characteristics, mean 
ADC values, and SUVmax have been found to be useful 
features for differentiating between high­risk and low­
risk GISTs [23]; high­risk GISTs tend to have lower mean 
ADC values and higher SUVmax when compared with low­
risk GISTs and non­GISTs [23]. The utility of minimum 
ADC values, as opposed to mean ADC values, has not 
been investigated. 
Vascular tumours
Vascular STT are classified as benign (haemangioma and 
epithelioid haemangioma), intermediate/locally aggres­
sive (kaposiform haemangioendothelioma), intermedi­
ate/rarely metastasising (haemangioendothelioma and 
Kaposi sarcoma), and malignant (epithelioid haemangio­
endothelioma and angiosarcoma of soft tissue). Two new 
entities, pseudomyogenic haemangioendothelioma (and 
also known as epithelioid sarcoma‐like haemangioendo­
thelioma), have been added to the intermediate (rarely 
metastasising) vascular tumour category. Pseudomyo­
genic haemangioendothelioma tends to be very avid on 
18F­FDG PET/CT, which can be useful for the detection 
of deep lesions [24]. The clinical course of patients with 
pseudomyogenic haemangioendothelioma is character­
ised by repeated local recurrence or the development of 
new tumour nodules within the same anatomical region, 
but metastasis is very rare [2]. The relationship between 
margin status and risk of disease recurrence has not been 
established, and at this point conservative management 
is the treatment of choice [25]. Although there have been 
new insights into the molecular genetics of malignant 
vascular tumours, the classification of de novo as well 
post­radiation angiosarcoma and epithelioid haeman­
gioendothelioma and its implications for radiologists has 
remained the same [2]. 
Nerve sheath tumours
Peripheral nerve sheath tumours (PNSTs) are included 
in the WHO soft tissue tumour classification rather than 
tumours of the central nervous system. Although several 
newly described histological variants of benign PNSTs have 
been included, there have been no changes to the classifica­
tion of malignant peripheral nerve sheath tumours. Benign 
PNSTs include schwannoma (and its variants), melanotic 
schwannoma, neurofibroma (and its variants), plexiform 
neurofibroma, perineurioma, granular cell tumours, der­
mal nerve sheath myxoma, ectopic meningioma, nasal glial 
heterotopia, benign triton tumour, and lastly hybrid nerve 
sheath tumours (which have features of more than 1 type of 
conventional PNSTs). The most common hybrid lesions are 
a hybrid schwannoma and perineurioma, which is typically 
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sporadic, and a hybrid neurofibroma/schwannoma, which 
is associated with type 1 neurofibromatosis [26].
Of the various STTs, advanced MRI sequences such as 
DWI and ADC mapping have been particularly useful for 
the distinction of benign PNSTs from malignant PNSTs. 
First, a morphological target sign visible on fluid sensi­
tive and contrast­enhanced MRI sequences is indicative 
of a benign PNST (both schwannoma and neurofibroma) 
[27] and rarely presents in a malignant peripheral nerve 
tumour. The qualitative presence of target sign (Figure 8) 
is more often seen on DWI using high b­values and ADC 
mapping based on the intrinsic T2 properties of a PNST 
compared with routine MRI sequence, and suggests the 
preservation of the PNSTs internal histological architec­
ture [27]. In addition, quantitative ADC values have also 
been used as a biomarker for malignancy in people with 
PNSTs [28,29] including nerve tumour syndromes such as 
NF1 [30]. Mean PNST diameter (> 4.2 cm) and minimum 
ADC value (≤ 1.0 × 10­3 mm2/s) are potentially important 
parameters that may be used to distinguish malignant 
PNSTs from benign PNSTs with high diagnostic accuracy 
[28]. In people with NF1, minimum ADC value ≤ 1.0 × 
10­3 mm2/s offers a high specificity of 94% while maintain­
ing a perfect sensitivity of 100% for malignancy [30]. As 
Figure 8. 16-year-old girl with neurofibroma. Axial T2-weighted fat-suppressed (A) and T1-weighted fat-suppressed post-contrast (B) magnetic reso-
nance(MR) images through the left proximal thigh show a small enhancing soft tissue mass along the sciatic nerve (arrows) with a target sign seen in (A). 
DWI using low b-value of 50 s/mm² (C), intermediate b-value of 400 s/mm² (D), high b-value of 800 s/mm² (E), and lastly the ADC map (F) (arrows) show 
a soft tissue mass with a target sign: suggesting preserved zonal histological architecture of a peripheral nerve sheath tumours (PNST). A morphological 
target sign can be visible on fluid-sensitive and contrast-enhanced MRI sequences and indicates a benign PNST. The qualitative presence of target sign is more 
often seen on DWI using high b-values and ADC mapping based on the intrinsic T2 properties of a PNST when compared with routine MRI sequences, and 
suggests the preservation of the PNST’s internal histological architecture. Mean PNST diameter (> 4.2 cm) and minimum ADC values (≤ 1.0 × 10-3 mm2/s) 
have been found to accurate quantitative metrics that can be used to distinguish malignant PNSTs from benign PNSTs
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such, advanced MRI sequences such as quantitative DWI 
are very useful in this particular subpopulation, who can 
have numerous PNSTs but also an inherently higher inci­
dence of malignancy. 
Limited data on patients with PNSTs suggests that MRS 
offers a highly sensitive (100%) but non­specific (50%) 
metabolic method of distinguishing malignant from be­
nign PNSTs. The added imaging and post­processing time 
associated with MRS in addition to slightly lower diagnostic 
accuracy has limited its utility in routine practice. 
Tumours of uncertain differentiation
Tumours of uncertain differentiation can be benign (such 
as intra­muscular myxoma and pleomorphic hyalinising 
angiectatic tumour [PHAT]), intermediate/locally ag­
gressive such as haemosiderotic fibrolipomatous tumour 
(HFLT), intermediate/rarely metastasising, which include 
benign and malignant varieties of phosphaturic mesen­
chymal tumour, and frankly malignant STT including 
synovial sarcoma (Figure 9), epithelioid sarcoma, alveolar 
soft­part sarcoma, clear cell sarcoma (Figure 10), and soft 
tissue extra­skeletal Ewing sarcoma as well as neoplasms 
with perivascular epithelioid cell differentiation.
Although PHATs tend to exhibit variable imaging fea­
tures, a solid subcutaneous mass with ill­defined margins 
in the extremity should raise the possibility of PHAT [31]. 
Of note, these features are rather similar to other benign 
and malignant STTs such as nodular fasciitis. HFLT, a lo­
cally aggressive STT of uncertain differentiation typi­
cally occurring in middle‐aged women, most commonly 
around the ankle or wrist, is an un­encapsulated, large 
tumour with high rate of local recurrence estimated at 
50% if incompletely excised [2]. On MRI, HFLT presents 
as a soft tissue mass with indistinct margins, intralesional 
fat, and septations with local recurrence and occasionally 
blood products on GRE [32]. PMT, which is classified as 
a rarely metastasising lesion, is an extremely rare but clini­
cally and histologically distinctive tumour that produces 
fibroblast growth factor 23, a hormone that blocks the 
reuptake of phosphate by proximal renal tubule, resulting 
in phosphaturia [33]. As such, PMTs produce phospha­
turia and result in tumour‐induced osteomalacia, which 
resolves with complete PMT excision [34]. Clinically, the 
Figure 9. 17-year-old male with reported right-sided neck swelling found to be synovial sarcoma. On coronal (A) and axial (B) fluid-sensitive fat-suppressed 
magnetic resonance (MR) images through the neck, there is a circumscribed somewhat heterogeneous high signal intensity mass centred within the right 
parapharyngeal and submandibular spaces (arrow), measuring approximately 3.6 × 3.8 × 8.1 cm (AP by TR by CC). C) The mass demonstrates avid slightly 
heterogeneous enhancement on the T1-weighted fat-suppressed axial MR image (arrow). By routine MRI sequences, the lesion is characterised as an 
indeterminate solid soft tissue mass that requires biopsy
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Figure 10. 30-year-old woman with recurrent clear cell sarcoma. Axial T2-weighted magnetic resonance (MR) image (A) and ADC map (B) through the upper 
lumbar spine show a right paraspinal unencapsulated soft tissue mass (arrow) of heterogeneously low signal intensity. There is qualitative restricted diffusion on 
DWI using low b-value of 50 s/mm² (C), intermediate b-value of 400 s/mm² (D), and high b-value of 800 s/mm² (E) with lack of signal loss on DWI with increas-
ing b-values. On the axial ADC map (B), there is qualitative restricted diffusion or low signal and quantitatively low ADC values, compatible with malignancy. 
Sagittal STIR MR image (F) shows perilesional oedema and internal septations within the mass (arrow). There is early arterial enhancement on DCE MIP (G) and 
heterogeneous enhancement on axial T1-wighted fat-suppressed post-contrast axial MR image (H) (arrows). Features of malignancy include restrictive diffusion 
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majority of patients with PMT exhibit elevated serum lev­
els of fibroblast growth factor 23 [33]. PMTs tend to have 
a non­specific imaging appearance and can mimic TS­
GCT, and even ALT [35]. Of note, the majority of PMTs 
tend to exhibit variable hypointensity on T2­weighted 
imaging, radiotracer uptake on 99mTc­sestamibi scintigra­
phy, and 111In­pentetreotide scintigraphy, as well as 68Ga­
Dotate PET/CT and 18F­FDG PET/CT (mean SUVmax was 
4.1 ± 2.5 with a range of 1.5­10.8) [35].
Malignant tumours of uncertain differentiation tend to 
have aggressive MRI features. Of these, alveolar soft­part 
sarcomas (ASPS) tend to exhibit eight MRI features more 
often: deep location relative to the superficial fascia, elevat­
ed signal on T1­weighted imaging, intralesional necrosis, 
lack of fibrotic component, infiltrative growth pattern, ab­
sence of tail sign, presence of intra­ and perilesional flow­
voids, and more than five flow voids suggesting neovascu­
larity [36]. Although these features are not diagnostic of 
ASPS, their presence is compatible with the diagnosis and 
suggests an aggressive histology that should be referred to 
a sarcoma centre and worked up appropriately. 
Lastly, similar to bone tumours, the term primitive 
neuroectodermal tumour has been removed as a synonym 
for Ewing sarcoma. 
Undifferentiated/unclassified sarcoma
This new category recognises sarcomas that cannot be 
classified into any of the other categories and includes 
undifferentiated varieties of spindle cell, pleomorphic 
(Figure 11), round cell, epithelioid, and not otherwise 
specified STS. Undifferentiated sarcoma is distinct from 
de­differentiated sarcoma because sarcomas in the un­
differentiated category lack clinical or morphological 
features that would otherwise place them under specific 
types of sarcomas, while dedifferentiated sarcomas tend to 
have some similarity to an adult tissue type. UPS was pre­
viously likely to be diagnosed as MFH. Undifferentiated/
unclassified sarcomas account for up to 20% of all sarco­
mas, and approximately 25% of these are radiation­asso­
ciated STS [2]. Similar to malignant fibroblastic myofibro­
blastic tumour (myxofibrosarcoma), a tail sign, defined 
as thick fascial enhancement extending from the sarcoma 
margin, is also a feature of undifferentiated sarcomas and 
is associated with locoregional recurrence [37]. Although 
there are no discrete regions of nodular enhancement 
along the tail sign or enhancing fascia, tumour infiltra­
tion along the fascia and subcutaneous fibrous septa is 
detected on histology [37]. As such, detection of the tail 
sign associated with a soft tissue mass is particularly im­
portant for pre­operative planning and resection of tu­
mour margins [37]. There are no large series investigating 
the advanced MRI features of undifferentiated varieties of 
sarcoma.
Conclusions
There have been several molecular and genetic advances 
relating to STT biology incorporated into the most recent 
WHO classification. The diagnostic accuracy of routine 
MRI sequences remains less than perfect for the major­
ity of STTs, due to overlapping features, especially after 
determinate soft tissue masses such as lipoma and gan­
glia are excluded. A benefit to characterisation has been 
shown with the use of advanced MRI sequences (DWI, 
DCE­MRI) [38,39]. There are some STTs that can be di­
agnosed with high accuracy based on imaging charac­
teristics and location, such as PNSTs (schwannoma and 
neurofibroma), palmar/plantar fibromatosis, fibromatosis 
colli, eslatofibroma dorsi, and lipomatosis. In the absence 
of these determinate entities, the primary role of MRI is to 
perform local staging of an indeterminate STT rather than 
provide an accurate histological diagnosis. Solid, indeter­
minate STTs should be referred to a sarcoma centre for 
a percutaneous biopsy and ultimately definitive manage­
ment because a multidisciplinary approach is critical for 
Figure 11. 61-year-old woman with grade 3 undifferentiated pleomorphic sarcoma. There is a large 9.6 × 1.5 × 7.4 cm soft tissue mass in the left gluteus 
maximus muscle (arrows). The mass is hyperintense relative to skeletal muscle T2-weighted fat-suppressed magnetic resonance (MR) image through the 
left hemipelvis (A) and isointense to skeletal muscle on T1-weighted image (B) with moderately heterogeneous enhancement on post-contrast T1-weighted 
fat-suppressed image (C). Aggressive MRI features include presence of tumoural necrosis and perilesional oedema/enhancement. There is no extra-com-
partmental extension 
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optimal outcomes for patients with these rare neoplasms. 
Important imaging features of a particular STT that must 
be included in a radiological interpretation are the longest 
lesional dimension, relationship to the superficial fascia 
(superficial or deep), and the presence of intra­tumoural 
necrosis, perilesional oedema/enhancement, and extra­
compartmental extension. Advanced MRI sequences can 
be helpful for the presence of hypercellularity (denoted 
by qualitative restrictive diffusion and quantitatively low 
ADC values) and neovascularity (visually seen as early 
arterial enhancement on DCE sequences) suggesting 
14. Walker EA, Petscavage JM, Brian PL, et al. Imaging features of super­
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2012: 215810. 
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agnosis. Eur Radiol 2019; 29: 3441­3449.
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aggressive tumour behaviour. Because the most recent 
WHO update on STT incorporates tumour biology as an 
integral feature of STT classification, advanced quantita­
tive MRI sequences will increasingly serve as an impor­
tant tool in the diagnosis and management of these chal­
lenging tumours.
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